XERS

5.46

0.36% -0.02

Dopo l'orario di chiusura: 5.51 0.05 +0.92%

Xeris Biopharma Holdings Inc (XERS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.48

Aprire:

$5.47

Volume 24 ore:

1.47M

Relative Volume:

0.71

Capitalizzazione di mercato:

$941.47M

Reddito:

$246.03M

Utile/perdita netta:

$-32.00M

Rapporto P/E:

-25.69

EPS:

-0.2125

Flusso di cassa netto:

$-16.78M

1 W Prestazione:

-6.02%

1M Prestazione:

-19.94%

6M Prestazione:

-27.10%

1 anno Prestazione:

+19.74%

Intervallo 1D:

$5.41

$5.615

Intervallo di 1 settimana:

$5.382

$5.865

Portata 52W:

$3.805

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Nome

Xeris Biopharma Holdings Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

844-445-5704

Indirizzo

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Dipendente

435

Cinguettio

@XerisPharma

Prossima data di guadagno

2024-12-08

Ultimi documenti SEC

XERS's Discussions on Twitter

Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
XERS Xeris Biopharma Holdings Inc	5.46	941.47M	246.03M	-32.00M	-16.78M	-0.2125
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Overweight
2025-08-12	Ripresa	H.C. Wainwright	Buy
2024-11-11	Downgrade	Piper Sandler	Overweight → Neutral
2024-03-28	Iniziato	Oppenheimer	Outperform
2023-08-28	Iniziato	Craig Hallum	Buy
2022-10-21	Iniziato	Jefferies	Buy
2022-04-28	Iniziato	Craig Hallum	Buy
2021-11-17	Iniziato	SVB Leerink	Outperform
2021-10-29	Iniziato	H.C. Wainwright	Buy
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2020-02-18	Iniziato	Piper Sandler	Overweight
2018-07-16	Iniziato	Jefferies	Buy
2018-07-16	Iniziato	Leerink Partners	Outperform
2018-07-16	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie

Mar 11, 2026

Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com

Mar 11, 2026

XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView

Mar 11, 2026

Mar 09, 2026

Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com

Mar 09, 2026

Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - Sahm

Mar 09, 2026

Mar 07, 2026

XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 07, 2026

Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn

Mar 07, 2026

Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat

Mar 07, 2026

Xeris Biopharma: Q4 Earnings Snapshot - JG-TC.com

Mar 07, 2026

Mar 06, 2026

Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo

Mar 06, 2026

Mar 05, 2026

Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus

Mar 05, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 05, 2026

Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus

Mar 05, 2026

Mar 04, 2026

Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat

Mar 04, 2026

Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro

Mar 04, 2026

Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha

Mar 04, 2026

HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat

Mar 04, 2026

Mar 03, 2026

XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance

Mar 03, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 03, 2026

Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia

Mar 03, 2026

Mar 02, 2026

Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal

Mar 02, 2026

Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat

Mar 02, 2026

Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative - simplywall.st

Mar 02, 2026

Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 02, 2026

Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat

Mar 02, 2026

Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan

Mar 02, 2026

XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView

Mar 02, 2026

Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan

Mar 02, 2026